Bevacizumab improves tumor infiltration of mature dendritic cells and effector T-cells in triple-negative breast cancer patients.
NPJ Precis Oncol
; 5(1): 62, 2021 Jun 29.
Article
in En
| MEDLINE
| ID: mdl-34188163
A single dose of bevacizumab reduced the density of angiopoietin-2-positive vessels while improving the infiltration of CD4+ T and CD8+ T cells, and mature dendritic cells in patients with primary triple-negative breast cancer. Our findings provide a rationale for including bevacizumab during neoadjuvant treatment to enhance the efficacy of immune checkpoint blockers in this disease.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
NPJ Precis Oncol
Year:
2021
Document type:
Article
Affiliation country:
United States
Country of publication:
United kingdom